^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | LY3143921 (CDC7 kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A CR-UK Phase I Trial of LY3143921
Excerpt:
Histological or cytological diagnosis of incurable, advanced/metastatic cancer For Phase Ia (dose escalation): Enriched for patients with tumours associated with p53 mutation or loss of function:...urothelial cancer
Trial ID: